[{"orgOrder":0,"company":"Cytel","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Fluvoxamine","moa":"Serotonin transporter","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Cytel","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cytel \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cytel \/ Inapplicable"},{"orgOrder":0,"company":"SigmaDrugs Research Ltd.","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Fluvoxamine","moa":"Serotonin transporter","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"SigmaDrugs Research Ltd.","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"SigmaDrugs Research Ltd. \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"SigmaDrugs Research Ltd. \/ Inapplicable"},{"orgOrder":0,"company":"Asceneuron","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Fluvoxamine","moa":"Serotonin transporter","graph1":"Undisclosed","graph2":"Phase I","graph3":"Asceneuron","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Asceneuron \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Asceneuron \/ Inapplicable"}]

Find Clinical Drug Pipeline Developments & Deals for Desiflu

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          02

                          Peptide Process CMC
                          Not Confirmed
                          Peptide Process CMC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          January 30, 2024

                          Lead Product(s) : Fluvoxamine

                          Therapeutic Area : Undisclosed

                          Highest Development Status : Phase I

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          Peptide Process CMC
                          Not Confirmed
                          Peptide Process CMC
                          Not Confirmed

                          Details : According to research study data, Fluvoxamine was found to reduce the number of COVID-19 patients ending up in hospital by approximately 30 percent.

                          Product Name : Luvox

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          September 13, 2021

                          Lead Product(s) : Fluvoxamine

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase III

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          SigmaDrugs Research Ltd.

                          Country arrow
                          Peptide Process CMC
                          Not Confirmed

                          SigmaDrugs Research Ltd.

                          Country arrow
                          Peptide Process CMC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          January 22, 2021

                          Lead Product(s) : Fluvoxamine

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          Peptide Process CMC
                          Not Confirmed
                          Peptide Process CMC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          August 02, 2016

                          Lead Product(s) : Fluvoxamine

                          Therapeutic Area : Undisclosed

                          Highest Development Status : Phase I

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          Moscow Research Institute of Psychiatry

                          Country arrow
                          Peptide Process CMC
                          Not Confirmed

                          Moscow Research Institute of Psychiatry

                          Country arrow
                          Peptide Process CMC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          December 19, 2013

                          Lead Product(s) : Fluvoxamine

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Phase IV

                          Sponsor : Abbott Laboratories

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          07

                          Sha'ar Menashe Mental Health Center

                          Country arrow
                          Peptide Process CMC
                          Not Confirmed

                          Sha'ar Menashe Mental Health Center

                          Country arrow
                          Peptide Process CMC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          April 16, 2013

                          Lead Product(s) : Fluvoxamine

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Undisclosed

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank